January 1, 2025

Comprehensive analysis of

View Full Paper

Ask AI

Bookmark

KRAS mutations were present in 28.1% of patients with advanced solid tumors, influencing treatment outcomes.
Among 1667 patients, the highest frequency of single-nucleotide variants occurred in pancreatic cancer at 89.9%.
The retrospective cohort study identified common KRAS mutations like G12D, which affected patient survival rates.
Insights from this analysis may guide future clinical management for patients with KRAS aberrations.

Discussion

No takes yet. Share an insight, caveat, or question.

Retrospective cohort study reveals 28.1% KRAS aberrations in metastatic solid tumors, indicating survival impact of specific mutations.

Jung et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark